Skip to content
National Association of Attorneys General
  • For Members
    • How Do I…?
    • Member Benefits
    • Scholarships & Nominations
    • Specialized Services
    • Committees
    • Office Support
    • Member Directory
    • Account & Access
  • Events & Training
    • Event Calendar
    • Upcoming Programs
    • Training Opportunities
    • On-Demand Resources
    • CLE Credit
    • Mobile Training Requests
    • Our Faculty
  • Resources
    • Policy Letters
    • Reports & Publications
    • Research & Data
    • Attorney General Journal
    • Newsroom
    • Databases & Tools
    • Public Resources
  • Attorney Generals
    • What Attorneys General Do
    • Attorneys General Office 101
    • Find my AG
    • How AGs Are Selected
    • Issues Attorney Generals Work On
    • Consumer Complaint Guidance
    • Attorney General Elections
    • Past Attorneys General
    • Careers in Attorney General Offices
  • NAMFCU
    • History of NAMFCU
    • About NAMFCU
    • NAMFCU
    • About the Medicaid Fraud Control Units
    • NAMFCU Trainings
    • MFCU Member Hub
    • Reporting Fraud and Abuse
    • Careers with a MFCU
  • About
    • About Us
    • NAAG History
    • Leadership
    • Staff
    • Regions
    • Careers at NAAG
    • FAQs
    • SAGE
    • Contact Us
  • Log In
PUBLIC RESOURCES           NEWSROOM           CONTACT US
FIND MY AG         CREATE ACCOUNT
National Association of Attorneys General
  • For Members
    • How Do I…?
    • Member Benefits
    • Scholarships & Nominations
    • Specialized Services
    • Committees
    • Office Support
    • Member Directory
    • Account & Access
  • Events & Training
    • Event Calendar
    • Upcoming Programs
    • Training Opportunities
    • On-Demand Resources
    • CLE Credit
    • Mobile Training Requests
    • Our Faculty
  • Resources
    • Policy Letters
    • Reports & Publications
    • Research & Data
    • Attorney General Journal
    • Newsroom
    • Databases & Tools
    • Public Resources
  • Attorney Generals
    • What Attorneys General Do
    • Attorneys General Office 101
    • Find my AG
    • How AGs Are Selected
    • Issues Attorney Generals Work On
    • Consumer Complaint Guidance
    • Attorney General Elections
    • Past Attorneys General
    • Careers in Attorney General Offices
  • NAMFCU
    • History of NAMFCU
    • About NAMFCU
    • NAMFCU
    • About the Medicaid Fraud Control Units
    • NAMFCU Trainings
    • MFCU Member Hub
    • Reporting Fraud and Abuse
    • Careers with a MFCU
  • About
    • About Us
    • NAAG History
    • Leadership
    • Staff
    • Regions
    • Careers at NAAG
    • FAQs
    • SAGE
    • Contact Us
  • Log In

Determining Synthetic Nicotine’s Place in the Tobacco and Nicotine Regulation Landscape

Home / Public Health / Determining Synthetic Nicotine’s Place in the Tobacco and Nicotine Regulation Landscape
June 2, 2021 Public Health, Tobacco and E-cigarettes
Share this

Synthetic nicotine, sometimes referred to as “tobacco-free nicotine,” is a man-made chemical version of nicotine that is not derived from tobacco. Recently, several synthetic nicotine products have entered the market and, with them, questions on how they will be regulated. The U.S. Food and Drug Administration (FDA) regulates all products that are “made or derived from tobacco,” but this leaves a potential federal regulatory gap for synthetic nicotine not made or derived from tobacco.1 Until the FDA makes an official decision on how treat synthetic nicotine, the products remain on the market.

The Family Smoking Prevention and Tobacco Control Act of 2009, which amended the federal Food, Drug and Cosmetic Act, gave the FDA the authority to regulate the manufacturing, sale, and marketing of cigarettes, roll-your-own tobacco, and smokeless tobacco, and created FDA’s Center for Tobacco Products (CTP). Through issuance of the so-called “deeming rule” in August 2016, the FDA extended its jurisdiction to additional tobacco products, including e-cigarettes, pipe tobacco, cigars, and hookah. The FDA has broad regulatory authority over all products made or derived from tobacco and intended for human consumption. This authority covers areas such as modified risk claims, sale and marketing restrictions, and product standards.2

The FDA has made limited public statements on synthetic nicotine. According to its website, “E-liquids that do not contain nicotine or other substances made or derived from tobacco may still be components or parts and, therefore, subject to FDA’s tobacco control authorities.” The FDA will make determinations whether to regulate particular synthetic nicotine products on a “case-by-case basis.”

As the synthetic nicotine market grows, public health groups are urging the FDA to act either through CTP or FDA’s Center for Drug Evaluation and Research (CDER), which regulates drugs. The definition of a drug under 21 U.S.C. § 321(g) includes “articles (other than food) intended to affect the structure or any function of the body of man or other animals.” Researchers at the Public Health Law Center argue that since synthetic nicotine affects the structure of the brain, regulating synthetic nicotine as a drug would be the logical approach and would avoid allowing those products to fall into a regulatory gap. If the FDA regulates synthetic nicotine as a drug, synthetic nicotine manufacturers would likely have to take their products off the market and submit a new drug application.3

One synthetic nicotine product that is currently causing controversy is Puff Bar, an electronic cigarette. Puff Bar was originally sold as a disposable tobacco-nicotine based E-cigarette when the FDA ordered its removal in July 2020 due to various violations of the Food, Drug and Cosmetic Act, including lack of FDA authorization to market the product.4 This was an important step for curbing youth use of nicotine products. Based on the 2020 National Youth Tobacco Survey, use of disposable e-cigarettes increased 1000% from 2019 among high school students, with Puff Bar being the most popular product.5 However, in early 2021 the makers of Puff Bar announced they were returning to the market, claiming that their “nicotine-based products are crafted from a patented manufacturing process, not from tobacco,” and thus implicitly claiming the products are not subject to FDA jurisdiction. Puff Bar also claims that their nicotine is “purer than tobacco-containing or -derived nicotine” and “without the residual impurities of tobacco-derived nicotine.”6 These claims have not been evaluated, and little to nothing is known about their nicotine manufacturing process. Puff Bar has used the potential regulatory gap of synthetic nicotine to side-step the FDA’s processes and advertising restrictions. Several public health groups have written to the FDA urging it to remove Puff Bar from the market and to clarify the status of all synthetic nicotine products.7

Congress could ensure that the FDA has jurisdiction over synthetic nicotine products like Puff Bar by amending the definition of “tobacco product” in the Food, Drug and Cosmetic Act to include products containing nicotine, regardless of the source of the nicotine. Moreover Section 916 of that Act, titled “Preservation of State and Local Authority,” now provides that states and localities may enact and enforce measures relating to the sale or distribution of tobacco products.8 Accordingly, if the definition of “tobacco product” were thus amended,  states or localities could enact and enforce laws to prohibit or restrict the sale of synthetic nicotine products or certain categories of those products, such as those with flavors. Such measures would be likely to survive judicial challenge, as courts have consistently upheld local laws banning the sale of flavored tobacco products against claims that such laws are preempted by the Act as regulations of product standards.9

  1. 21 USC § 321(rr)(1) provides: “The term ‘tobacco product’ means any product made or derived from tobacco that is intended for human consumption, including any component, part, or accessory of a tobacco product (except for raw materials other than tobacco used in manufacturing a component, part, or accessory of a tobacco product).’ [↩]
  2.  Pub. L. No. 111-31, 123 Stat. 1776 (2009).  [↩]
  3. Zettler PJ, Hemmerich N, Berman ML. Closing the Regulatory Gap for Synthetic Nicotine Products. Boston Coll Law Rev. 2018;59(6):1933-1982. [↩]
  4. U.S. Food and Drug Administration. 2020. FDA Notifies Companies, Including Puff Bar, to Remove Flavored Disposable E-Cigarettes and Youth-Appealing E-Liquids from Market for Not Having Required Authorization. [↩]
  5. Wang, T., Gentzke, A., Neff, L., Glidden, E., Jamal, A., Park-Lee, E., Ren, C., Cullen, K., King, B. and Hacker, K., 2021. Disposable E-Cigarette Use among U.S. Youth — An Emerging Public Health Challenge. New England Journal of Medicine, 384(16), pp.1573-1576.

    [↩]

  6. Truth Initiative. 2021. What you need to know about new synthetic nicotine products. [online] Available at: <https://truthinitiative.org/research-resources/harmful-effects-tobacco/what-you-need-know-about-new-synthetic-nicotine-products> [↩]
  7. see footnote 3 [↩]
  8. Food, Drug and Cosmetic Act, Section 916(a)(1), 21 U.S.C. § 387p(a)(1). Certain other state or local measures are preempted under the Act, such as those relating to product standards, misbranding, and adulteration, that are different from or in addition to those contained in the Act. Id., Section 916(a)(2)(A), 21 U.S.C. § 387p(a)(2)(A). [↩]
  9. See, e.g., Nat’l Ass’n of Tobacco Outlets, Inc. v. City of Providence, 731 F.3d 71 (1st Cir. 2013); U.S. Smokeless Tobacco Mfg. Co. LLC v. City of New York, 708 F.3d 428 (2d Cir. 2013). [↩]

Related Posts

Related Posts

2026 Annual Beginner’s Guide to the Tobacco Master Settlement Agreement (MSA) & Tobacco and Nicotine Regulation Training

Shows no photo available image placeholder

Bipartisan Coalition of 45 Attorneys General Backs Pharmacy Benefit Manager (PBM) Transparency Rule

Shows no photo available image placeholder

Bipartisan Coalition of 45 Attorneys General Backs PBM Transparency Rule

Latest News

  • Bipartisan Coalition of 45 Attorneys General Backs Pharmacy Benefit Manager (PBM) Transparency Rule April 17, 2026
  • Supreme Court Report, Volume 33, Issue 10 April 8, 2026
  • Supreme Court Report, Volume 33, Issue 9 April 1, 2026
  • Bipartisan Coalition of Attorneys General Urges Congress to Pass Legislation Against Illicit Xylazine March 31, 2026
  • Supreme Court Report, Volume 33, Issue 8 March 23, 2026

Recent Posts

  • Bipartisan Coalition of 45 Attorneys General Backs Pharmacy Benefit Manager (PBM) Transparency Rule
  • Supreme Court Report, Volume 33, Issue 10
  • Supreme Court Report, Volume 33, Issue 9
  • Bipartisan Coalition of Attorneys General Urges Congress to Pass Legislation Against Illicit Xylazine
  • Supreme Court Report, Volume 33, Issue 8

Stay Connected

Get NAAG updates and training alerts.

Create an account and then select your preferred mailings (otherwise, we will send you everything).

Create Account
Set Marketing Preferences
Log In to Your Account
White Logo for the National Association of Attorneys General

1850 M Street NW, Suite 1200
Washington, DC  20036
Telephone: (202) 326-6000
support@naag.org

Our Work

  • Bankruptcy
  • Consumer Protection
  • Tobacco and Public Health
  • Center for Supreme Court Advocacy

Resources

  • Attorney General Journal
  • CLE Policy and Guidelines
  • Event Calendar
  • NAAG Policy Letters
  • Reports & Publications

ABOUT

  • Leadership
  • Staff
  • NAAG History
  • Mission Foundation
  • Careers at NAAG
  • Contact Us

© 2026 Copyright National Association of Attorneys General

Website by Yoko Co

Internal Feedback / Report an Error

Request an Update / Report an Error

The change you are requesting will be linked to this page. The URL for the page will be included in a hidden field when the form is submitted.
Please enter your change or describe your request. Be sure to reference where the error appears on the page and what needs to be done specifically.
Upload any files that need to be linked to this page. PDF only. Submit another request if you have more than five files to upload.
Drop files here or
Accepted file types: pdf, docx, xls, Max. file size: 128 MB, Max. files: 5.

    Who is requesting this change?(Required)

    Scroll To Top

    Insert/edit link

    Enter the destination URL

    Or link to existing content

      No search term specified. Showing recent items. Search or use up and down arrow keys to select an item.
        This site is registered on Toolset.com as a development site.
        To provide you more clarity about how we collect, store and use personal information, and your rights to control that information, we have updated our privacy policy, which also explains how we use cookies. You consent to our cookies if you continue to use our website.